公开(公告)号：US10526416B2

公开(公告)日：2020-01-07

申请号：US15508112

申请日：2015-09-08

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef Yarden ,  Nadège Gaborit ,  Moshit Lindzen

IPC: C07K16/00 ,  A61K39/395 ,  C07K16/32 ,  A61K47/68 ,  C07K16/30 ,  G01N33/574 ,  A61K39/00 ,  C07K16/28

Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a KD value of 10 nM or lower, wherein the polypeptide inhibits neuregulin (NRG) binding to the human HER3 and NRG-induced cancer cell migration and proliferation. Additionally clones NG83 and NG140 are provided which bind human HER-3 with a KD value of 10 nM or lower.

公开(公告)号：US20170122950A1

公开(公告)日：2017-05-04

申请号：US15358162

申请日：2016-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Moshit Lindzen ,  Yosef Yarden

IPC: G01N33/574 ,  G01N33/577 ,  C07K16/22

CPC classification number: G01N33/57484 ,  A61K31/7068 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/5011 ,  G01N33/57423 ,  G01N33/57438 ,  G01N33/57492 ,  G01N33/577 ,  G01N2333/485 ,  G01N2333/495 ,  G01N2500/00 ,  A61K2300/00

Abstract: A method of selecting a target for treatment of a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising analyzing an amount and/or activity of at least one ErbB ligand in a biological sample from the subject, wherein an ErbB ligand which shows an up-regulated amount and/or activity compared to a non-hyperproliferative cell or tissue above a predetermined level is selected as a target for treatment of the hyperproliferative disease. Methods of treating hyperproliferative diseases, monoclonal antibodies and pharmaceutical compositions are also disclosed.